Roberto Nico Dallocchio

Mr. Roberto Nico Dallocchio

Istituto di Chimica Biomolecolare CNR, Sassari, Sardegna, Italy
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMario Sechi
Mario Sechi
MDMassimiliano Derudas
Massimiliano Derudas
Roberto Nico DallocchioRoberto Nico Dallocchio
Roberto Nico Dallocchio
Alessandro DessìAlessandro Dessì
Alessandro Dessì
ABAlessia Bacchi
Alessia Bacchi
NNNouri Neamati
Nouri Neamati

1 July 2020 in Journal of Chromatography A
Verified
Journal Article
Closed access
Paola PelusoPaola Peluso
Paola Peluso
Victor MamaneVictor Mamane
Victor Mamane
Roberto Nico DallocchioRoberto Nico Dallocchio
Roberto Nico Dallocchio
Alessandro DessìAlessandro Dessì
Alessandro Dessì
SCSergio Cossu
Sergio Cossu

1 October 2013 in Journal of Virology
Verified
Journal Article
Open access
PDF file
ASAnnelies Stevaert
Annelies Stevaert
Roberto Nico DallocchioRoberto Nico Dallocchio
Roberto Nico Dallocchio
Alessandro DessìAlessandro Dessì
Alessandro Dessì
NPNicolino Pala
Nicolino Pala
DRDominga Rogolino
Dominga Rogolino
LNLieve Naesens
Lieve Naesens
The influenza virus PA endonuclease, which cleaves capped host pre-mRNAs to initiate synthesis of viral mRNA, is a prime target for antiviral therapy. The diketo acid compound L-742,001 was previously identified as a potent inhibitor of the influenza virus endonuclease reaction, but information on its precise binding mode to PA or potential resistance profile is limited. Computer-assisted docking of L-742,001 into the crystal structure of inhibitor-free N-terminal PA (PA-Nter) indicated a binding orientation distinct from that seen in a recent crystallographic study with L-742,001-bound PA-Nter (R. M. DuBois et al., PLoS Pathog. 8:e1002830, 2012). A comprehensive mutational analysis was performed to determine which amino acid changes within the catalytic center of PA or its surrounding hydrophobic pockets alter the antiviral sensitivity to L-742,001 in cell culture. Marked (up to 20-fold) resistance to L-742,001 was observed for the H41A, I120T, and G81F/V/T mutant forms of PA. Two- to 3-fold resistance was seen for the T20A, L42T, and V122T mutants, and the R124Q and Y130A mutants were 3-fold more sensitive to L-742,001. Several mutations situated at noncatalytic sites in PA had no or only marginal impact on the enzymatic functionality of viral ribonucleoprotein complexes reconstituted in cell culture, consistent with the less conserved nature of these PA residues. Our data provide relevant insights into the binding mode of L-742,001 in the PA endonuclease active site. In addition, we predict some potential resistance sites that should be taken into account during optimization of PA endonuclease inhibitors toward tight binding in any of the hydrophobic pockets surrounding the catalytic center of the enzyme.

22 May 2014 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
GPGiovanna Pani
Giovanna Pani
BSBarbara Scherm
Barbara Scherm
EAEmanuela Azara
Emanuela Azara
VBVirgilio Balmas
Virgilio Balmas
ZJZahra Jahanshiri
Zahra Jahanshiri
GDGiovanna Delogu
Giovanna Delogu

2 February 2019 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
Paola PelusoPaola Peluso
Paola Peluso
Alessandro DessìAlessandro Dessì
Alessandro Dessì
Roberto Nico DallocchioRoberto Nico Dallocchio
Roberto Nico Dallocchio
Victor MamaneVictor Mamane
Victor Mamane
SCSergio Cossu
Sergio Cossu

1 February 2005 in Antiviral Chemistry and Chemotherapy
Verified
Journal Article
Closed access
MSMario Sechi
Mario Sechi
LSLuciano Sannia
Luciano Sannia
FCFabrizio Carta
Fabrizio Carta
MPMichele Palomba
Michele Palomba
Roberto Nico DallocchioRoberto Nico Dallocchio
Roberto Nico Dallocchio
NNNouri Neamati
Nouri Neamati
HIV-1 integrase (IN) is an attractive and validated target for the development of novel therapeutics against AIDS. Significant efforts have been devoted to the identification of IN inhibitors using various methods. In this context, through virtual screening of the NCI database and structure-based drug design strategies, we identified several pharmacophoric fragments and incorporated them on various aromatic or heteroaromatic rings. In addition, we designed and synthesized a series of 5-aryl(heteroaryl)-isoxazole-3-carboxylic acids as biological isosteric analogues of β-diketo acid containing inhibitors of HIV-1 IN and their derivatives. Further computational docking studies were performed to investigate the mode of interactions of the most active ligands with the IN active site. Results suggested that some of the tested compounds could be considered as lead compounds and suitable for further optimization.